Hint mode is switched on Switch off

Vanda Pharmaceuticals, ordinary share
VNDA, US9216591084

FIND, SAVE & TRACK INVESTMENTS WITH CBONDS WATCHLIST

With Cbonds Watchlist you can always stay updated on your investments to make conscious decisions!

Watchlist
You need to request access
Add a stock to WL
Choose all Reset all
Vanda Pharmaceuticals, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
No data
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest quotes

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Analysts forecasts

  • median ***
  • average ***
  • min ***
  • max ***

Issuer

  • Issuer
  • Full borrower / issuer name
    Vanda Pharmaceuticals Inc.
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    VNDA
  • Placement
    12.04.2006
  • Lock up period
    180
  • Number of papers
    5,750,000
  • Volume of raised funds
    57.5 mln USD
  • Final placement price
    10 USD
  • Price change since placement date
    -45.6%
  • By capitalization
    216.44 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    VNDA
  • Placement
    29.10.2014
  • Lock up period
    180
  • Number of papers
    5,000,000
  • Volume of raised funds
    58 mln USD
  • Placement share
    12.85%
  • Final placement price
    11.6 USD
  • Price change since placement date
    -100%
  • By capitalization
    451.25 mln USD
  • Placement type
    SPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    VNDA
  • Placement
    16.03.2018
  • Lock up period
    180
  • Number of papers
    5,500,000
  • Volume of raised funds
    93.5 mln USD
  • Placement share
    10.9%
  • Final placement price
    17 USD
  • Price change since placement date
    -100%
  • By capitalization
    857.45 mln USD
Other placements of the issuer Hide

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
II q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show more Hide

Related Stock indices

Indicators

News

10/03/2026 Vanda Pharmaceuticals: Shall Not Be Deemed “filed” For The Purposes Of Section 18 Of The Securities Exchange Act Of 1934 (as Amended, The “exchange Act”) Or Otherwise Subject To The Liabilities Of That Section, Nor Shall Such Information Be Deemed Incorporated By Reference In Any Filing Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing
07/05/2025 Vanda Pharmaceuticals: Of This Current Report On Form 8k And Exhibit 99.1 Attached Hereto Shall Not Be Deemed “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall It Be Deemed Incorporated By Reference In Any Filing Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Expressly Set Forth By Specific Reference In Such A Filing, Financial Statements And Exhibits
06/11/2024 Vanda Pharmaceuticals: Of This Current Report On Form 8k And Exhibit 99.1 Attached Hereto Shall Not Be Deemed “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall It Be Deemed Incorporated By Reference In Any Filing Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Expressly Set Forth By Specific Reference In Such A Filing
15/10/2024 Vanda Pharmaceuticals: Other Events, Financial Statements And Exhibits
24/05/2024 Vanda Pharmaceuticals: Other Events, Financial Statements And Exhibits
All organization news

Holders

Industry Leaders

Registration is required to get access.